PCMTD1P2

Across TCGA pan-cancer cohorts, PCMTD1P2 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated PCMTD1P2 data layer.

The strongest signal is observed in thymoma (THYM), where higher PCMTD1P2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PCMTD1P2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

THYM, PAAD, and KIRP are the cancer types where PCMTD1P2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Tertile	All	0.090	0.862	<.001	126	view →
PAAD	DFS	Tertile	All	0.006	0.505	<.001	45	view →
KIRP	DFS	Tertile	II,III,IV	0.519	0.783	<.001	33	view →
MESO	DFS	Tertile	All	0.099	0.392	.030	27	view →
THCA	OS	Tertile	II,III,IV	0.240	0.829	.023	21	view →
OV	OS	Tertile	IV	0.310	0.638	.023	18	view →
LUSC	OS	Tertile	II,III,IV	0.521	0.780	<.001	18	view →
LIHC	DFS	Tertile	All	0.014	0.527	<.001	9	view →
SARC	OS	Tertile	All	0.643	0.830	.027	6	view →
STAD	DFS	Quartile	II,III,IV	0.442	0.563	.041	4	view →
SKCM	OS	Tertile	All	0.913	0.775	.032	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

PCMTD1P2–THYM (OS)

Open the THYM breakdown →